<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002323</url>
  </required_header>
  <id_info>
    <org_study_id>200B</org_study_id>
    <secondary_id>BIPI 1037</secondary_id>
    <nct_id>NCT00002323</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell</brief_title>
  <official_title>A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      PRIMARY: To compare the virologic activity (quantitative RNA PCR, quantitative PBMC) of the&#xD;
      combination of nevirapine and zidovudine (AZT) versus AZT alone after 3 and 6 months of&#xD;
      treatment. To compare the effects of these two regimens on CD4 T-cell count and percentage.&#xD;
&#xD;
      SECONDARY: To compare and evaluate other markers of immunologic and virologic activity in&#xD;
      patients receiving nevirapine/AZT versus AZT alone. To compare the effects of the two&#xD;
      regimens on clinical signs and symptoms. To evaluate the safety and tolerance of the two&#xD;
      regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive combination nevirapine/AZT or AZT alone. Patients are evaluated for&#xD;
      virologic and immunologic activity at 3 and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>60</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  PCP prophylaxis (trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine),&#xD;
             at the discretion of the investigator.&#xD;
&#xD;
          -  Antifungal prophylaxis with oral fluconazole or ketoconazole.&#xD;
&#xD;
          -  Antiviral prophylaxis for herpes simplex virus with &lt;= 1000 mg/day oral acyclovir.&#xD;
&#xD;
          -  Dilantin for prevention and treatment of seizures.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Asymptomatic HIV infection.&#xD;
&#xD;
          -  CD4 count 200-500 cells/mm3.&#xD;
&#xD;
          -  No prior AIDS.&#xD;
&#xD;
          -  No history of or active HIV-related thrush, vaginal candidiasis, zoster (shingles),&#xD;
             excessive weight loss, persistent fever, or diarrhea.&#xD;
&#xD;
          -  Tolerated 500-600 mg AZT daily for at least 4 months but no more than 12 months&#xD;
             immediately prior to study entry.&#xD;
&#xD;
          -  Consent of parent or guardian if less than 18 years of age.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Patients may not co-enroll in another protocol involving other investigational drugs&#xD;
             or biologics.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Malignancy other than limited cutaneous basal cell carcinoma.&#xD;
&#xD;
          -  Psychiatric condition sufficient to impair study compliance.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemic glucocorticoids and steroid hormones.&#xD;
&#xD;
          -  Dicumarol, warfarin, and other anticoagulant medications.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Doxycycline.&#xD;
&#xD;
          -  Chloramphenicol.&#xD;
&#xD;
          -  Phenobarbital and other barbiturates.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
          -  Amoxicillin-clavulanate (Augmentin).&#xD;
&#xD;
          -  Ticarcillin clavulanate.&#xD;
&#xD;
          -  Biologic response modifiers (alpha interferon, IL-2, immune modulators).&#xD;
&#xD;
          -  Any investigational drugs other than study drugs.&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
        History of clinically important disease other than HIV infection, that may put patient at&#xD;
        risk because of participation in this study.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral medications other than AZT.&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Immunosuppressive or cytotoxic drugs or other experimental drugs.&#xD;
&#xD;
          -  Systemic glucocorticoids and steroid hormones.&#xD;
&#xD;
          -  Dicumarol, warfarin, and other anticoagulant medications.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Doxycycline.&#xD;
&#xD;
          -  Chloramphenicol.&#xD;
&#xD;
          -  Phenobarbital and other barbiturates.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
          -  Amoxicillin-clavulanate (augmentin).&#xD;
&#xD;
          -  Ticarcillin clavulanate.&#xD;
&#xD;
          -  Biologic response modifiers (alpha interferon, IL-2, immune modulators).&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  AZT at 500-600 mg/day for at least 4 months but no more than 12 months immediately&#xD;
             preceding study entry.&#xD;
&#xD;
        Chronic use of alcohol or drugs sufficient to impair study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Highland Gen Hosp / San Francisco Gen Hosp</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>946021018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ Med School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>775550882</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2002</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Nevirapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

